Table 3 Multivariate analysis of the association between prognostic variables and survival in cervical cancer patients

FIGO stage (IB2/IIB vs. IB1/IIA)

1.72 [0.86–3.47], 0.090

2.00 [0.70–5.73], 0.190

Cell type (AD vs. SCC)

3.80 [2.10–6.86], <0.001

5.89 [2.37–14.65], <0.001

LN metastasis

4.15 [2.20–7.83], <0.001

2.89 [1.12–7.49], 0.030

Tumor size (>4 cm)

0.96 [0.49–1.88], 0.910

0.90 [0.32–2.54], 0.840

PM involvement

1.31 [0.58–2.94], 0.520

1.72 [0.52–5.69], 0.380

FGFR1+

0.52 [0.25–1.11], 0.090

0.48 [0.16–1.50], 0.210

FGFR2+

0.51 [0.27–0.97], 0.040

0.24 [0.07–0.83], 0.020

FGFR3+

0.56 [0.30–1.03], 0.060

0.29 [0.11–0.78], 0.010

FGFR4+

0.51 [0.28–0.91], 0.020

0.33 [0.13–0.83], 0.020

FGFR2+/FGFR3+

0.37 [0.17–0.82], 0.010

0.13 [0.03–0.60], 0.010

FGFR2+/FGFR4+

0.30 [0.13–0.68], 0.004

0.17 [0.05–0.63], 0.008

FGFR3+/FGFR4+

0.33 [0.15–0.69], 0.004

0.11 [0.03–0.44], 0.002

FGFR2+/FGFR3+/FGFR4+

0.24 [1.10–0.60], 0.002

0.08 [0.02–0.40], 0.002